PDCD1 and neoplasm: Since cancer immunotherapy is discovered through inhibition of immune checkpoints by James P. Allison and Tasuku Honjo [1–3], programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have been considered important “brake” molecules in tumor immunity [4].